Annual Drug Patent Validity Period for YUPELRI
Yupelri is a drug marketed by Mylan Ireland Ltd and included in one NDA. It is available from a single supplier. There are seventeen patents protecting this drug.
YUPELRI drug price trends.
Drug patent litigation for YUPELRI.
This drug has sixty-four patent family members in thirty-one countries.
The generic ingredient in YUPELRI is revefenacin. One registered supplier for this compound. Additional details are available on the revefenacin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for the Mylan Ireland drug YUPELRI